This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Bibliografia
Holloway RG (1996) Cost-effectiveness analysis: what is it and how will it influence neurology. Ann Neurol 39(6):818–823
Richards RG, Sampson FC, Beard SM, Tappenden P (2002) A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 6(10):3–73
Clegg A, Bryant J, Milne R (2000) Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technol Assess 4(9):i–iv, 1–101
Parkin D, McNamee P, Jacoby A et al (1998) A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess 2(4):3–54
Parkin D, Jacoby A, McNamee P et al (2000) Treatment of multiple sclerosis with interferon b: an appraisal of cost-effectiveness and quality of life. JNNP 68(2):144–149
Vickrey BG, Hays RD, Harooni R et al (1995) A health-related quality of life measure for multiple sclerosis. Qual Life Res 4(3):187–206
Williams A (1995) The role of the EUROQOL instrument in QALY calculations. Centre for Health Economics, University of York, York
Forbes RB, Lees A, Waugh N, Swingler RJ (1999) Population-based cost utility study of interferon beta 1b in secondary progressive multiple sclerosis. BMJ 319(7224):1529–1533
European study group on interferon beta-1b in secondary progressive MS (1998) Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 352(9139):1491–1497
Nuijten MJ, Hutton J (2002) Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health 5(1):44–54
Brown MG, Murray TJ, Sketris IS et al (2000) Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression: first estimates. Int J Technol Assess Health Care 16(3):751–767
The IFNB multiple sclerosis study group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 43(4):655–661
Sketris IS, Brown MG, Murray TJ et al (1996) Drug therapy in multiple sclerosis. A study of Nova Scotia Senior citizens. Clin Therapeutics 18(2):303–318
Kendrick M, Johnson KI (2000) Long-term treatment of multiple sclerosis with interferon-â may be cost effective. Pharmacoeconomics 18(1):45–53
Murphy N, Confavreux C, Haas J et al (1998) Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics 13:607–622
Phillips CJ, Gilmour L, Gale R, Palmer M (2001) A cost utility model of interferon beta 1b in the treatment of relapsing-remitting multiple sclerosis. J Med Econ 4:35–50
Kobelt G, Jonsson L, Henriksson F et al (2000) Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis. Int J Technol Assess Health Care 16(3):768–780
Kobelt G, Jonsson L, Miltenburger C, Jonsson B (2002) Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis using natural history disease data. Int J Technol Assess Health care 18(1):127–138
Henriksson F, Jonsson B (1998) The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics 13:597–606
Weinshenker BG, Brass B, Rice GP et al (1989) The natural history of multiple sclerosis: A geographically based study, I: Clinical course and disability. Brain 112(6):133–146
Weinshenker BG, rice GP. Noseworthy JH et al (1991) The natural history of multiple sclerosis: A geographically based study, II: Multivariate analysis of predictive factors and models of outcome. Brain 114(2):1045–1056
Nicholson T, Milne R (1996) Copolymer 1 in relapsing-remitting multiple sclerosis. (Report n. 63) Wessex Institute for Health Research and Development. Development and Evaluation Committee, Southampton
Johnson KP, Brooks BR, Cohen JA et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of the phase III multicenter, doubleblind, placebo-controlled trial. Neurology 45(7):1268–1276
Bose U, Ladkani D, Burrell A, Sharief M (2001) Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. J Med Econ 4:207–219
Touchette DR, Durgin TL, Wankle LA, Goodkin DE (2003) A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in secondary progressive or progressive-relapsing multiple sclerosis. Clin Therapeutics 25(2):611–634
Rubio-Terres C, Aristegui RI, Medina Redondo F, Izquierdo A (2003) Cost-utility analysis of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain. Farm Hosp 27(3):159–165
Hollendorf DA, Jilinskaia E, Oleen-Burkey M (2002) Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 8(6):469–476
Chilcott J, McCabe C, Tappenden P et al (2003) Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 326(7388):522–527
Patzold U, Pocklington PR (1982) Course of multiple sclerosis: first results of a prospective study carried out on 102 MS patients from 1976–80. Acta Neurol Scand 65(4):248–266
Kobelt G, Lindgren P, Parkin D et al. Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the UK. Scandinavian working papers in Economics 2000 (http://swopec.hhs.se/hastef/papers/hastef0398.pdf)
Rights and permissions
Copyright information
© 2005 Springer-Verlag Italia
About this chapter
Cite this chapter
Amato, M., Portaccio, E. (2005). Studi farmacoeconomici: revisione della letteratura. In: Costi sociali e aspetti farmacoeconomici. Aspetti psico-sociali della sclerosi multipla, vol 4. Springer, Milano. https://doi.org/10.1007/88-470-0401-2_6
Download citation
DOI: https://doi.org/10.1007/88-470-0401-2_6
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0327-9
Online ISBN: 978-88-470-0401-6
eBook Packages: MedicineMedicine (R0)